USPTO Director Overturns PTAB Decision, Rekindling Hormonal Disorder Treatment Innovation
In a recent development, the director of the U.S. Patent and Trademark Office (USPTO) has overturned a Patent Trial and Appeal Board (PTAB) decision that declined to re-evaluate a biotech firm’s patent pertaining to a hormonal disorder treatment. The reversal came on Friday, and it was a significant move by Andrei Iancu, the USPTO Director….